AWKNF News and Press, Awakn Life Sciences

Toronto, Ontario--(Newsfile Corp. - July 18, 2024) - Awakn Life Sciences Corp. (CSE: AWKN) (OTCQB: AWKNF) (FSE: 954) ("Awakn" or the "Company"), a clinical-stage biotechnology company developing therapeutics for substance use and mental health disorders, with a near-term focus on Alcohol Use Diso...

2024-05-07 05:54:17 ET More on psychedelic therapies MindMed: Breakthrough Status From FDA For LSD Therapy COMPASS Pathways: Will MDMA-Assisted Therapy Pave The Way? Mind Medicine: GAD Program Success Continues With BTD MindMed releases promising data on LSD-...

Toronto, Ontario--(Newsfile Corp. - May 2, 2024) - Awakn Life Sciences Corp. (CSE: AWKN) (OTCQB: AWKNF) (FSE: 954) ("Awakn" or the "Company"), a clinical-stage biotechnology company developing medication-assisted treatments for addiction with a near-term focus on Alcohol Use Disorder (AUD), annou...

Toronto, Ontario--(Newsfile Corp. - April 17, 2024) - Awakn Life Sciences Corp. (CSE: AWKN) (OTCQB: AWKNF) (FSE: 954) ("Awakn" or the "Company") a clinical-stage biotechnology company developing medication-assisted treatments for addiction with a near-term focus on Alcohol Use Disorder (AUD), is ...

2024-04-03 08:41:23 ET More on Awakn Life Sciences Financial information for Awakn Life Sciences Read the full article on Seeking Alpha For further details see: Awakn Life Sciences inks licensing partnership deal with Oklahoma-based clinic

Awakn also announces Private Placement Toronto, Ontario--(Newsfile Corp. - April 3, 2024) - Awakn Life Sciences Corp. (CSE: AWKN) (OTCQB: AWKNF) (FSE: 954) ("Awakn" or the "Company") a clinical-stage biotechnology company developing medication-assisted treatments for addiction with a near-term f...

Toronto, Ontario--(Newsfile Corp. - Le 9 février/February 2024) - The common shares of Awakn Life Sciences Corp. have been approved for listing on the CSE. Listing and disclosure documents will be available at www.thecse.com on the trading date. Awakn Life Sciences Corp. is a clinic...

Toronto, Ontario--(Newsfile Corp. - February 12, 2024) - Awakn Life Sciences Corp. (CBOE: AWKN) (OTCQB: AWKNF) (FSE: 954) ("Awakn"), a clinical-stage biotechnology company developing medication-assisted treatments for addiction with a near-term focus on Alcohol Use Disorder ("AUD"), is pleased to...

Toronto, Ontario--(Newsfile Corp. - February 5, 2024) - Awakn Life Sciences Corp. (CBOE: AWKN) (OTCQB: AWKNF) (FSE: 954) ("Awakn"), a clinical-stage biotechnology company developing medication-assisted treatments for addiction with a near-term focus on Alcohol Use Disorder ("AUD"), is pleased to ...

Awakn Designates Program AWKN-002 for Alcohol Use Disorders in the US Market Toronto, Ontario--(Newsfile Corp. - January 24, 2024) - Awakn Life Sciences Corp. (CBOE: AWKN) (OTCQB: AWKNF) (FSE: 954) ("Awakn"), a clinical-stage biotechnology company developing medication-assisted treatments for ad...